Recursion Prescribed drugs (RXRX) CFO and President of Recursion UK, Ben Taylor, joined a fireplace chat on the 2026 KeyBanc Capital Markets Healthcare Digital Discussion board on March 17, 2026, at 3:45 PM EDT.
Scott Schoenhaus, healthcare tech fairness analyst at KeyBanc Capital Markets, moderated the dialogue. He welcomed attendees and prompted Taylor to introduce himself and the corporate, emphasizing current transformations over the previous 12 to 24 months.
Taylor’s Path from Exscientia Merger
Taylor traced his profession from the Exscientia aspect of the merger accomplished 18 months in the past. He served as CFO and Chief Technique Officer at Exscientia for greater than 4 years previous to the mixture.
“I used to be truly coming over from the Exscientia aspect of the merger,” Taylor acknowledged. “I used to be the CFO and Chief Technique Officer over at Exscientia and had been there for a bit over 4 years after we introduced the businesses collectively 18 months in the past.”
Palms-On Biotech Expertise
Earlier than Exscientia, Taylor oversaw day-to-day operations at an oncology biotech agency. He gained direct perception into scientific trial setup, website visits, and FDA interactions.
“I had truly run the day-to-day operations at an oncology biotech,” he shared. “So obtained to see what it was like actually digging in and establishing scientific trials, going out to the scientific trial websites, working with the FDA.”
Shift to AI-Pushed Drug Discovery
Taylor’s biotech function uncovered important gaps in drug growth information. He noticed that sparse info led to guesswork amongst groups and shoppers from his earlier banking profession.
This problem impressed his pivot to AI-based drug discovery, the place superior instruments leverage rising information to tell selections extra successfully.
